Locating Spravato (esketamine) treatment centers within a specific geographic area, such as the 20902 ZIP code, necessitates identifying qualified healthcare providers authorized to administer this medication. Spravato is a nasal spray approved for treatment-resistant depression and depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions. Its controlled administration requires certification and monitoring due to potential side effects.
Accessing Spravato treatment offers potential benefits for individuals who have not responded adequately to traditional antidepressant therapies. The availability of this treatment option within a defined locality allows patients to receive care closer to their residences, potentially reducing travel burdens and improving treatment adherence. The historical context involves the need for alternative treatments for severe depression, leading to the development and approval of esketamine as a novel approach.
